IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 3,760,000 shares, a growth of 768.0% from the January 31st total of 433,200 shares. Approximately 6.5% of the company’s stock are short sold. Based on an average daily volume of 4,930,000 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of IN8bio

Several hedge funds have recently added to or reduced their stakes in INAB. BIOS Capital Management LP purchased a new position in shares of IN8bio during the 4th quarter valued at $2,212,000. Alyeska Investment Group L.P. raised its position in shares of IN8bio by 1,064.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after buying an additional 4,628,482 shares in the last quarter. Jane Street Group LLC boosted its stake in IN8bio by 296.7% during the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after buying an additional 86,696 shares during the period. Geode Capital Management LLC grew its position in IN8bio by 56.5% during the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after buying an additional 185,919 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in IN8bio during the fourth quarter worth about $1,465,000. Institutional investors own 92.05% of the company’s stock.

IN8bio Stock Performance

NASDAQ:INAB traded up $0.02 during trading on Friday, reaching $0.27. The company’s stock had a trading volume of 2,848,412 shares, compared to its average volume of 7,817,839. IN8bio has a 12 month low of $0.22 and a 12 month high of $1.74. The firm has a market cap of $19.51 million, a price-to-earnings ratio of -0.36 and a beta of 0.05. The firm has a 50 day moving average of $0.28 and a 200-day moving average of $0.32. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of IN8bio in a research report on Wednesday, February 12th.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.